It's a shame to say, but if you bought and are still holding shares of Bluebird Bio (NASDAQ: BLUE) or Teladoc Health (NYSE: TDOC) at practically any point in the last three years, you've lost money. Between the bear market in the Nasdaq, the market's recent distaste for overvalued growth stocks, bad news, and the pair's weak earnings, the last 12 months have been especially difficult for investors.

And there's a solid chance that the next 12 months (and beyond) will be just as hard. So, as tempting as it might be to buy the dip with these two stocks, you should probably invest in more appealing companies instead. Here's why.

Bluebird's business is to develop gene therapies for rare diseases, and on Aug. 17, its medicine called beti-cel (also known as Zynteglo) for beta thalassemia, a rare hereditary blood disorder, was approved by the Food and Drug Administration (FDA).

Continue reading

Source Fool.com